Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.46%
- Poor long term growth as Operating profit has grown by an annual rate 23.63% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 27.74%, it has a Very Expensive valuation with a 3.97 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.49%
0%
-18.49%
6 Months
33.88%
0%
33.88%
1 Year
190.58%
0%
190.58%
2 Years
422.58%
0%
422.58%
3 Years
362.86%
0%
362.86%
4 Years
123.83%
0%
123.83%
5 Years
57.09%
0%
57.09%
Shanghai Henlius Biotech, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
56.45%
EBIT Growth (5y)
23.63%
EBIT to Interest (avg)
-4.03
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.91
Sales to Capital Employed (avg)
0.66
Tax Ratio
3.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.46%
ROE (avg)
10.54%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
3.97
EV to EBIT
16.66
EV to EBITDA
11.63
EV to Capital Employed
2.56
EV to Sales
2.52
PEG Ratio
0.30
Dividend Yield
NA
ROCE (Latest)
15.34%
ROE (Latest)
27.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
6,206.60
5,961.40
4.11%
Operating Profit (PBDIT) excl Other Income
1,345.40
1,095.00
22.87%
Interest
133.20
122.10
9.09%
Exceptional Items
0.00
-23.50
100.00%
Consolidate Net Profit
889.60
603.30
47.46%
Operating Profit Margin (Excl OI)
151.30%
117.10%
3.42%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.11% vs 59.47% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 47.46% vs 174.62% in Dec 2023
About Shanghai Henlius Biotech, Inc. 
Shanghai Henlius Biotech, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






